Zoetis Reports Thursday With Options Traders More Cautious Than Usual

ZTS reports Q3 results on Thursday morning having recovered sharply from its year-long slide, up 6.1% over the past week to $82.99 and 19% over the past month, a rebound that has outpaced all of its closest peers by a wide margin.

Options traders are not fully convinced the rally holds. The put/call ratio has climbed to 0.54, nearly two standard deviations above its 20-day average of 0.48, the most defensive positioning in options on this stock in several months. That said, the lending market tells a different story: short interest at 4.1% of the free float is modest, borrow costs remain negligible at 0.46%, and availability is extremely loose, meaning there is no sign of meaningful short pressure building in the run-up to the print.

The analyst picture is split. Morgan Stanley holds an Overweight rating but trimmed its target to $82 this week, almost exactly where the stock already trades, leaving almost no implied upside in a nominally positive call. Goldman Sachs initiated at Neutral with a $74 target last month, a floor below the current price. Against that, UBS nudged its Neutral target up to $85 from $80 on October 27. The consensus sits at Hold, three buys against eleven holds, with a mean target of $88.38. The bull case rests on Zoetis's pipeline in companion animal products and a loyal customer base that has historically proved resilient. Bears point to premium valuation, disease-outbreak risk, and the ongoing staffing and inflationary pressures in veterinary practices. The PE multiple has expanded almost two full points over the past 30 days as the share price recovered, adding pressure on the company to deliver on Thursday.

Retail attention is running elevated. Wikipedia views for Zoetis are tracking 2.1 standard deviations above the prior 90-day average as of October 28, the highest reading in recent months, reflecting broader interest as the print approaches. No alt-data series for Zoetis has been measured to lead its reported financials, so the reading is colour rather than signal.

Thursday's report will test whether the Q3 numbers justify both the recent price recovery and the compressed upside that most of the analyst community is now willing to put behind a positive rating.